Metered dose inhaler market seen reaching $21.06 billion by 2030

The global metered dose inhaler devices market is projected to grow from $17.12 billion in 2026 to $21.06 billion by 2030, according to The Business Research Company. Rising COPD and asthma cases, air pollution, and demand for smarter inhalers are expected to keep fueling the market.

Why it matters: - Metered dose inhalers are a core delivery tool for asthma, COPD and other respiratory conditions. - The market’s projected growth points to sustained demand for inhalation therapies as respiratory disease rates rise worldwide. - A larger market could also accelerate adoption of smart inhalers, digital adherence tools and eco-friendlier propellants.

What happened: - The Business Research Company released its Metered Dose Inhaler Devices Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - The report says the market rose from $16.23 billion in 2025 to $17.12 billion in 2026, a 5.5% CAGR. - The report forecasts the market will reach $21.06 billion by 2030, growing at a 5.3% CAGR. - A free sample of the report is available here. - The full report is available here.

The details: - Metered dose inhaler devices are designed to deliver exact doses of aerosolized medication directly to the lungs with each inhalation. - MDIs are used to manage asthma, chronic obstructive pulmonary disease and other breathing disorders. - The report ties recent market growth to rising asthma and COPD incidence, broad use of inhalation therapies, physician preference for MDIs and the availability of generic inhaler options. - Future growth drivers include smart inhalers, stricter environmental rules on propellants, home healthcare expansion, digital adherence monitoring and new respiratory therapies. - Key trends include smart dose tracking, breath-actuated inhalation systems, smaller portable designs, improved dose accuracy and broader use of eco-friendly propellants. - In 2025, North America held the largest share of the global market. - The Asia-Pacific region is projected to grow the fastest during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests the market is shifting from basic inhaler hardware toward connected and more regulated device platforms. - Air quality concerns are becoming a stronger commercial driver because pollution increases respiratory disease burden and treatment demand. - The report’s growth case reflects both clinical need and policy pressure, especially around propellant emissions and monitoring adherence. - The cited COPD outlook from the National Institutes of Health underscores how long-term disease prevalence can support device demand. - The Clean Air Fund data cited in the release points to worsening air pollution as a broader public health issue that could keep lifting inhaler use.

What's next: - The market is expected to continue expanding through 2030 as respiratory disease prevalence rises and device technology advances. - Companies are likely to focus on smarter inhalers, more portable formats and greener propellant options. - Regional growth in Asia-Pacific may narrow the gap with North America if respiratory treatment access and demand keep rising. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards and market hotspot infographics.

The bottom line: - Metered dose inhalers are set for steady growth, with demand supported by rising respiratory illness, pollution pressures and a shift toward smarter, more efficient devices.